Certara Inc (CERT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Certara Inc stock (CERT) is currently trading at $6.10. Certara Inc PS ratio (Price-to-Sales) is 2.38. Analyst consensus price target for CERT is $9.19. WallStSmart rates CERT as Sell.
- CERT PE ratio analysis and historical PE chart
- CERT PS ratio (Price-to-Sales) history and trend
- CERT intrinsic value — DCF, Graham Number, EPV models
- CERT stock price prediction 2025 2026 2027 2028 2029 2030
- CERT fair value vs current price
- CERT insider transactions and insider buying
- Is CERT undervalued or overvalued?
- Certara Inc financial analysis — revenue, earnings, cash flow
- CERT Piotroski F-Score and Altman Z-Score
- CERT analyst price target and Smart Rating
Certara Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Certara Inc (CERT) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Certara Inc (CERT) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
118.49% of shares held by major funds and institutions
Supporting Valuation Data
Certara Inc (CERT) Areas to Watch (7)
Company is destroying shareholder value
Earnings declining -14.10%, profits shrinking
Company is losing money with a negative profit margin
Near-zero operating margins, business under pressure
Revenue growing slowly at 3.30% annually
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 2.38x sales
Certara Inc (CERT) Detailed Analysis Report
Overall Assessment
This company scores 34/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 2.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (0.94) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, EPS Growth, Profit Margin. Some valuation metrics including Price/Sales (2.38) suggest expensive pricing. Growth concerns include Revenue Growth at 3.30%, EPS Growth at -14.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -0.15%, Operating Margin at 2.08%, Profit Margin at -0.38%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -0.15% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 3.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CERT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CERT's Price-to-Sales ratio of 2.38x trades at a deep discount to its historical average of 9.36x (1th percentile). The current valuation is 91% below its historical high of 27.02x set in Oct 2021, and 2% above its historical low of 2.34x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~4.1x as trailing revenue scaled faster than the stock price.
Compare CERT with Competitors
Top HEALTH INFORMATION SERVICES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Certara Inc (CERT) · HEALTHCARE › HEALTH INFORMATION SERVICES
The Big Picture
Certara Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 419M with 330% growth year-over-year. The company is currently unprofitable, posting a -38.0% profit margin.
Key Findings
Revenue growing at 330% YoY, reaching 419M. This pace significantly outperforms most HEALTH INFORMATION SERVICES peers.
Generating 28M in free cash flow and 29M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -38.0% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Certara Inc maintain 330%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.58, so expect amplified moves relative to the broader market.
Sector dynamics: monitor HEALTH INFORMATION SERVICES industry trends, competitive moves, and regulatory changes that could impact Certara Inc.
Bottom Line
Certara Inc is a high-conviction growth story with revenue accelerating at 330% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -38.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Certara Inc(CERT)
NASDAQ
HEALTHCARE
HEALTH INFORMATION SERVICES
USA
Certara Inc. provides software products and technology services to clients for biosimulation in drug discovery, preclinical and clinical research, regulatory filings, and market access. The company is headquartered in Princeton, New Jersey.